Test-firing ammunition for spliceosome inhibition in cancer

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6064-6066

  Dehm, Scott M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; E 7107; INTEIN; PIPERAZINE DERIVATIVE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SPLICING ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; EXON; FATIGUE; HUMAN; INTRON; MYELODYSPLASTIC SYNDROME; NAUSEA; OPTIC NEURITIS; PRIORITY JOURNAL; PUBLICATION; RNA SPLICING; RNA TRANSLATION; SPLICEOSOME; STRUCTURE ACTIVITY RELATION; VISUAL DISORDER; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; EPOXY COMPOUNDS; FEMALE; HUMANS; MACROLIDES; MALE; NEOPLASMS; SPLICEOSOMES;

EID: 84888092496     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2461     Document Type: Article

References (12)

1. Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, et al. Phase I, pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res 2013;19:6296-304.
2. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 2013;14:153-65.
3. Golas MM, Sander B, Will CL, Luhrmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science 2003;300:980-4. (Pubitemid 36548885)
4. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007;8:749-61. (Pubitemid 47429207)
5. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010;24:2343-64.
6. Dehm SM. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res 2013;73:5309-14.
7. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007;3:570-5. (Pubitemid 47294394)
8. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007;3:576-83. (Pubitemid 47294395)
9. Hasegawa M, Miura T, Kuzuya K, Inoue A, Won Ki S, Horinouchi S, et al. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem Biol 2011;6:229-33.
10. Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol 2011;6:582-9.
11. Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 2011;25:440-4.
12. Cazzola M, Rossi M, Malcovati L. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013;121:260-9.